Market News & Trends
GT Biopharma Advances Into Cohort 3 of GTB-3650 Phase 1 Trial Following Safety Review of Cohort 2
GT Biopharma, Inc. recently announced initiation of dosing in Cohort 3 of its Phase 1 dose escalation trial evaluating GTB-3650 for the treatment of relapsed or…
Legend Biotech Reports Recent Highlights & Second Quarter Results
Legend Biotech Corporation recently reported its second quarter 2025 unaudited financial results and key corporate highlights. “The groundbreaking 5-year survival data from CARTITUDE-1, with one-third…
Nanexa Signs Continuation of Feasibility Agreement With Major Pharmaceutical Company to Investigate PharmaShell Long-Acting Formulations in a Multi-Billion US Market
Nanexa has recently announced the signing of an extension of a feasibility agreement with a major pharmaceutical company to investigate the use of Nanexa´s proprietary…
Assembly Biosciences Reports Positive Interim Results From Phase 1b Clinical Study of Long-Acting Helicase-Primase Inhibitor Candidate Showing Reductions in Viral Shedding Rate & Genital Lesion Rate in Recurrent Genital Herpes
Assembly Biosciences, Inc. recently announced positive interim antiviral activity, clinical outcomes, safety, and pharmacokinetic (PK) results from a Phase 1b study evaluating ABI-5366, an investigational…
Genmab Announces Phase 3 Trial Met Dual Primary Endpoints in Patients With Relapsed/Refractory Follicular Lymphoma
Genmab A/S recently announced positive results of the Phase 3 EPCORE FL-1 trial evaluating subcutaneous epcoritamab, a bispecific antibody, in combination with rituximab andlenalidomide (R2) versus…
Almirall & Absci Expand AI Drug Creation Collaboration Adding a Second Dermatology Target
Almirall and Absci Corporation recently announced the expansion of their ongoing AI Drug Discovery collaboration with Almirall’s selection of a second target aimed at dermatological indications.…
Parkinson’s Disease Market to Grow to $7 Billion by 2033
The Parkinson’s disease (PD) market across the seven major markets (7MM) is forecast to grow at a compound annual growth rate (CAGR) of 7.6% from…
Aragen Appoints Aniel Khubchandani as CEO of Development & Manufacturing Solutions Business
Aragen recently announced the appointment of Aniel Khubchandani as CEO of its Development & Manufacturing Solutions business. Aniel will be a member of Aragen’s Management…
Sanofi Completes Acquisition of Vigil Neuroscience
Sanofi recently announced the completion of its acquisition of Vigil Neuroscience, Inc. This acquisition strengthens Sanofi’s early stage pipeline in neurology with VG-3927, a novel,…
Evoke Pharma Announces Issuance of New Patent for GIMOTI With Extended Exclusivity to Late 2038
Evoke Pharma, Inc. recently announced the official issuance of a new US patent related to its product GIMOTI. The patent, US Patent No. 12,377,064, covers…
Cardurion Pharmaceuticals Completes Enrollment in Phase 2 Trials Evaluating a Novel PDE9 Inhibitor in Heart Failure
Cardurion Pharmaceuticals, Inc. recently announced it has completed enrollment in two global, multi-center, Phase 2 clinical trials assessing the safety and efficacy of CRD-750 in…
Moleculin Biotech Reports Promising Preclinical Data of Annamycin in Liver Cancer Treatment
Moleculin Biotech, Inc. recently announced the presentation of encouraging preclinical data for its lead drug candidate, Annamycin, also known by its non-proprietary name of naxtarubicin, which…
Porosome Therapeutics Announces Breakthrough Alzheimer's Discoveries
Porosome Therapeutics, Inc. recently announced key advancements in its first-in-class, disease-modifying neurological platform, which will transform Alzheimer’s Disease (AD) research and treatment by offering a…
Polpharma Biologics & Fresenius Kabi Sign Licensing Agreement for Proposed Vedolizumab Biosimilar
Polpharma Biologics S.A. recently announced a global (except for Middle East & North Africa) licensing agreement with Fresenius Kabi for the commercialization of PB016, a…
Axplora Announces Significant Investment at Vizag Site & FDA Inspection Success Across Indian Operations
Axplora recently announced a significant investment at its Vizag site in India to expand production capacity and reinforce supply chain resilience. This announcement follows the…
Elicio Therapeutics Announces Positive Recommendation to Continue ELI-002 7P Randomized Phase 2 Study in Pancreatic Cancer Without Modifications to Final Analysis
Elicio Therapeutics, Inc. recently announced that following the Independent Data Monitoring Committee’s (IDMC) pre-specified interim review of the unblinded safety and efficacy data in the…
Pioneering LNP Expert Dr. Pieter Cullis Joins Hongene’s Scientific Advisory Board
Hongene, a global CDMO focused on nucleic acid raw materials and medicines, has appointed Dr. Pieter Cullis, a renowned innovator in lipid nanoparticle…
SERB Pharmaceuticals Agrees to Acquire Y-mAbs Therapeutics
SERB Pharmaceuticals and Y-mAbs Therapeutics, Inc. recently announced they have entered into a definitive merger agreement under which SERB will acquire Y-mAbs, including its lead…
Yatiri Bio Acquires NGeneBioAI to Expand AI-Powered Proteomics Platform & Advance Precision Biomarker Discovery
Yatiri Bio, Inc. recently announced the successful acquisition of NGeneBioAI, Inc., a San Diego-based company specializing in plasma proteomics and AI-powered diagnostics. The acquisition strengthens Yatiri…
Freya Pharma Solutions Announces Launch of Phase 2 Clinical Dose-Response Study Testing its Lybrido Concept Targeting Female Sexual Dysfunction
Freya Pharma Solutions recently announced the initation of a Phase 2 clinical study evaluating its Lybrido concept. The study will investigate two dose-combinations of testosterone…
